US5222936A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Intracorporeal iontophoretic method
Assignee: Physion Srl
•
Filing: 1991-09-25
•
Granted: 1993-06-29
•
Expires: 2011-09-25
Abstract
Abstract A method of intracorporeal iontophoretic treatment of an internal hollow body organ containing a physiological ion-rich fluid environment by delivery to said hollow body organ of drug ions by means of an iontophoretic device inserted into said hollow body organ and comprising an active electrode which has the same polarity as the drug ions to be delivered. The method comprises direct measurement of the pH of said physiological fluid environment, whereby indirectly measuring its ionic composition and selecting accordingly the material of said active electrode so that it either can interact with ions contained in said physiological environment or allow the interaction of said environmental ions with water hydrolysis products so as to reduce the ionic species competitive with said drug ions during the iontophoretic process.
Inventors
- 👤 Robert L. Stephen
- 👤 Franco Lugnani
- 👤 Cino Rossi
- 👤 Silvio Eruzzi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:28
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/18; A61N1/20; A61N1/30; A61N1/303; A61N1/306
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
150 words
An improved method of intracorporeal iontophoretic administration of ionized drugs to the competitive-ion rich urinary environment of the bladder or prostatic urethra comprising: feeding into the bladder or prostatic urethra an aqueous solution of a said ionized drug, inserting into the bladder or prostatic urethra an intracorporeal electrode designated to have the same polarity of the drug ions to be administered, electrically connecting said intracorporeal electrode to an external circuit comprising a source of electrical current and a counterelectrode, and applying electrical current from said source, wherein the improvement comprises: measuring the urine pH prior to said iontophoretic administration whereby assessing the predominant competitive-ions present in the urine, and selecting the material of said intracorporeal electrode in accordance with said pH measurement, the selected electrode material being capable of interacting with said competitive-ions in the urine so as to give products which do not interfere with the iontophoretic drug delivery.
Claim 2
Dependent Claim
150 words
An improved method of intracorporeal iontophoretic administration of ionized drugs to the competitive-ion rich urinary environment of the bladder or prostatic urethra comprising: feeding into the bladder or prostatic urethra an aqueous solution of a said ionized drug, inserting into the bladder or prostatic urethra an intracorporeal electrode designated to have the same polarity of the drug ions to be administered, electrically connecting said intracorporeal electrode to an external circuit comprising a source of electrical current and a counterelectrode, and applying electrical current from said source, wherein the improvement comprises: measuring the urine pH prior to said iontophoretic administration whereby assessing the predominant competitive-ions present in the urine, and selecting the material of said intracorporeal electrode in accordance with said pH measurement, the selected electrode material being capable of interacting with said competitive-ions in the urine so as to give products which do not interfere with the iontophoretic drug delivery.
Claim 3
Dependent Claim
34 words
A method according to claim 1 further comprising the step of manipulating the predominant urinary competitive-ions to a desired pH range prior to said iontophoretic administration by a preliminary dietary regulation or drug administration.
Claim 4
Dependent Claim
53 words
A method according to claim 1 or 2 for administering a cationic drug wherein the measured urinary pH is equal to or less than 6.5 indicating that the predominant urinary competitive-ions comprise chloride ions and wherein the anode to be used as intracorporeal electrode is selected from metals capable of forming chloride precipitates.
Claim 5
Dependent Claim
19 words
A method according to claim 3 wherein said anode is selected from the group consisting of silver and copper.
Claim 6
Dependent Claim
74 words
A method according to claim 1 or 2 for administering a cationic drug wherein the measured urinary pH is equal to or greater than 7.0 indicating that the predominant urinary competitive-ions comprise bicarbonate ions and monohydrogen phosphate ions and wherein the anode to be used as introcorporeal electrode is selected from essentially inert conductive materials whereby hydrogen ions formed at the anode by water hydrolysis will be available for reacting with said predominant competitive-ions.
Claim 7
Dependent Claim
25 words
A method according to claim 5 wherein said anode is selected from the group consisting of carbon, gold, platinum, stainless steel, chromium and nickel-chromium alloys.
Claim 8
Dependent Claim
49 words
A method according to claim 1 or 2 for administering a cationic drug wherein the measured urinary pH ranges from 6.5 to 7.0 and wherein the anode to be used as intracorporeal electrode is selected from the group consisting of essentially inert conductive materials and metals forming chloride precipitates.
Claim 9
Dependent Claim
71 words
A method according to claim 1 or 2 for administering an anionic drug wherein the measured urinary pH is equal or less than 6.5 indicating that the predominant competitive-ions comprise dihydrogen phosphate and wherein the cathode to be used as intracorporeal electrode is selected from conductive materials behaving as essentially inert cathodes whereby hydroxyl ions produced at the cathode by water hydrolysis will be available to react with said predominant competitive-ions.
Claim 10
Dependent Claim
26 words
A method according to claim 8 wherein said cathode is selected from the group consisting of gold, carbon, platinum, stainless steel, copper, chromium and nickel-chromium alloys.
References Cited (Backward Citations)
SU843999A1
Cited
SU825095A1
Cited
SU876138A1
Cited
SU1005796A1
Cited
SU1064956A1
Cited
US4744787A
Cited
US4747819A
Cited
US4752285A
Cited
US4915685A
Cited
US4752285B1
Cited
US5057072A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-06-28 | 1996-12-28 | 1997-06-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-06-28 | 2000-12-28 | 2001-06-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-06-28 | 2004-12-28 | 2005-06-29 | $7700.00 | Window Closed / Lapsed |